GSK In Talks To Buy Nuvalent For More Than $9 Billion, FT Says
GSK is in talks to acquire cancer biotech Nuvalent in a deal valued at more than $9 billion, the Financial Times reported. If completed, it would be GSK’s biggest acquisition in more than a decade, according to the report.
The reported discussions involve London-based GSK and Nuvalent, a U.S. biotechnology company focused on cancer drug development. The Financial Times said the potential transaction value would exceed $9 billion. The talks were also reported by Reuters and cited by other financial news outlets.
Neither company has announced an agreement. The reporting characterizes the situation as talks, not a finalized deal, and no timetable or additional terms were provided in the headlines cited.
The development matters because it would mark a major strategic move for GSK, returning the company to the scale of blockbuster dealmaking that it has not pursued in more than a decade. A transaction of this size would also underscore the continued premium that large drugmakers are willing to consider for oncology-focused biotechs, where successful drugs can become significant long-term revenue drivers.
For Nuvalent, a deal at this valuation would represent a major outcome for a biotech company developing cancer therapies and could shift its future from independent development to integration within a global pharmaceutical company’s research, regulatory, and commercial infrastructure.
For the broader market, the talks add to investor focus on mergers and acquisitions in the drug industry, where large companies routinely evaluate purchases to add pipeline assets and strengthen therapeutic portfolios. The reported value and the “biggest in over a decade” framing are likely to draw attention from shareholders, competitors, and regulators.
What happens next is whether the two sides can reach definitive terms. If discussions progress, the next step would typically be a formal announcement detailing price, structure, and any conditions. From there, a transaction of this size would be expected to face the usual closing requirements, which can include approvals and other customary conditions, though no specific process or hurdles were described in the reporting cited.
Until an agreement is announced, the situation remains a set of reported negotiations that would, if completed, reshape GSK’s deal history and place Nuvalent at the center of one of the largest biotech buyout discussions this year.
